Mergers and Acquisitions

* On April 29, 2013, Qiagen has announced the acquisition of Ingenuity Systems, a provider of software solutions to efficiently and accurately analyze and interpret the biological meaning of genomic data, for $105 million in cash (subject to customary purchase price adjustments). The acquisition of Ingenuity, which had 2012 net sales of approximately $20 million, was effective April 29, 2013, and funded from existing cash reserves. 
Qiagen will integrate Ingenuity’s solutions into its full-range ecosystem of  molecular testing solutions, such as PCR and next-generation sequencing.

Ingenuity is a privately-held U.S. company based in California’s Silicon Valley. It has created an expertly curated knowledge system of biomedical information and analysis solutions for the exploration, interpretation and analysis of complex biological systems. The foundation of Ingenuity’s product portfolio is the Ingenuity Knowledge Base, a 14-year effort to accurately, manually curate, model and computationally structure the vast amount of biomedical literature, including genomic variations implicated in human disease and thousands of disease models. The Ingenuity Knowledge Base and software applications enable users to accurately interpret the meaning of increasingly large amounts of biological data to better guide scientific experiments and medical treatment decisions. Ingenuity’s Knowledge Base is built on algorithms that pair all human gene variants with biological interpretations based on known outcomes and findings. These pairings are collected and reviewed by experts (curated) in a standardized way from a wide range of sources including clinical and scientific publications with the support of advanced technology and refined processes. This process and the associated learning algorithms translate sourced data into interoperable and linkable collections of relevant information.

Ingenuity product offerings include:

• Ingenuity® Pathways Analysis™ (IPA), a web-based software application that enables researchers to model, analyze and understand the complex biological systems at the core of life sciences research. It supports data analysis and interpretation from all high-throughput analysis platforms and is used in virtually all areas of drug discovery and development from target identification and validation to biomarkers, predictive toxicology and pharmacogenomics.

• Ingenuity® Variant Analysis™, a web-based NGS data analysis application that answers a critical need for researchers trying to rapidly identify relevant causal variants in human diseases in a matter of hours. It enables customers to rapidly identify and prioritize variants by drilling down to a small, targeted subset of compelling variants based upon published biological evidence and their own knowledge of disease biology. Customers can also interrogate variants from multiple biological perspectives, explore different biological hypotheses and identify the most promising variants for follow-up analysis.

• Ingenuity® iReport™ , an interactive web-based report optimized for gene expression experiments from RNA-Seq, microarray and real-time PCR platforms. It provides fast and accurate biological and statistical analysis of a customer’s biological data.GeneGlobe content portal. G
• GeneGlobe offers hundreds of assay panels for PCR and NGS as well as more than 60,000 fully annotated molecular assays for the most sought-after diseases and pathways, curated from the biomedical literature. 
Ingenuity is also developing a new product to enable broader adoption of NGS in molecular diagnostics by offering an optimized and scalable solution for interpreting and scoring clinical variants identified by sequencing-based molecular diagnostic tests.